KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Equity Investments: 2009-2010

Historic Gains from Equity Investments for Biomarin Pharmaceutical (BMRN) over the last 2 years, with Dec 2010 value amounting to $3.0 million.

  • Biomarin Pharmaceutical's Gains from Equity Investments fell 21.56% to $542,000 in Q1 2011 from the same period last year, while for Mar 2011 it was $2.8 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2010, which is 15.30% up from last year.
  • Biomarin Pharmaceutical's Gains from Equity Investments amounted to $3.0 million in FY2010, which was up 15.30% from $2.6 million recorded in FY2009.
  • Biomarin Pharmaceutical's Gains from Equity Investments' 5-year high stood at $3.0 million during FY2010, with a 5-year trough of $2.6 million in FY2009.
  • Its 2-year average for Gains from Equity Investments is $2.8 million, with a median of $2.8 million in 2009.
  • Data for Biomarin Pharmaceutical's Gains from Equity Investments shows a peak YoY grew of 15.30% (in 2010) over the last 5 years.
  • Over the past 2 years, Biomarin Pharmaceutical's Gains from Equity Investments (Yearly) stood at $2.6 million in 2009, then grew by 15.30% to $3.0 million in 2010.